Literature DB >> 18822706

An unusual presentation of secondary involvement of B-cell chronic lymphocytic leukemia. A case report.

Fausto Famà1, Valeria Barresi, Giuseppe Giuffrè, Paolo Todaro, Sergio Mazzei, Angelo Vindigni, Maria Gioffrè-Florio.   

Abstract

Extramammary tumors rarely metastasize to the breast. The commonest tumors to metastasize in breast tissue are lymphoproliferative diseases, melanoma, lung cancer and gynecological malignancies. Primary breast lymphoma has been reported in the literature with a maximum percentage of about 0.5% of all breast malignancies, while secondary localizations of lymphomas in the breast are less well studied in the literature than primary ones. The authors report a rare case of a secondary localization of B-cell chronic lymphocytic leukemia to the breast in which the diagnosis was obtained by histopathology and immunohistochemistry and further confirmed by molecular data. This occurrence must be considered in the differential diagnosis of a breast lump so that the primary hematological disease can be adequately treated and the correct type of breast surgery performed.

Entities:  

Mesh:

Year:  2008        PMID: 18822706     DOI: 10.1177/030089160809400431

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  3 in total

1.  Chronic lymphocytic leukemia involving the breast parenchyma, mimicker of invasive breast cancer: differentiation on breast MRI.

Authors:  Vandana Dialani; Kalpana Mani; Nicole B Johnson
Journal:  Case Rep Med       Date:  2013-09-18

2.  Small Lymphocytic Lymphoma Presenting as a Breast Lump: A Rare Presentation of Non-Hodgkin's Lymphoma.

Authors:  Nazia Khan; Hamid Shaaban; Gunwant Guron
Journal:  Cureus       Date:  2021-11-09

Review 3.  Male breast involvement in chronic lymphocytic leukemia. A case report and review of the literature.

Authors:  Vasiliki Anagnostopoulou; Niki Mantha; Konstantinos Sapalidis; Eirini Tolparidou; Elisavet Georgiou; Triantafyllia Koletsa
Journal:  Rom J Morphol Embryol       Date:  2020       Impact factor: 1.033

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.